Skip to main content

COVID 19 Updates from RheumNow

Methotrexate Monitoring (5.13.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

$30 Billion and Counting (4.29.2022)

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Pre-exposure Prophylaxis for COVID-19 (4.22.22)

Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).

Evusheld as Protective Therapy in High Risk COVID-19 Patients

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

Male vs. Female Responders (4.15.2022)

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Consensus Best Practices for Virtual Care in Rheumatology

The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.

ACR Fellow Training Subcommittee Report on Pandemic Experiences

Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training. 

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

FDA Authorizes 2nd Booster for Older and Immunocompromised Individuals

FDA

Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.

Are Shoulder Conditions Incited by Vaccination?

A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle. 

Consequences of TNF inhibition (3.18.2022)

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April! This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Social

FDA has approved baricitinib (Olumiant) for the Treatment of Certain Hospitalized Patients with COVID-19 who require supplemental O2, mechanical ventilation, ECMO. Rec dose: 4-mg once daily for 14 days or until hospital discharge https://t.co/RiEp01tc0v https://t.co/f3RvUAzdRp
Dr. John Cush @RheumNow ( View Tweet )
3 days 3 hours ago
Study of 198 RMD pts, vaccinated 91% JAKi and 80% MTX mono pts were Ab+ for spike protein. Adjusting MTX or JAKi did not significantly alter the immunogenicity (S1 spike Abs). DMARD adjustments w/ COVID-19 VAX may not be needed. https://t.co/ebw172M5I4 https://t.co/vjXqTbuD5t
Dr. John Cush @RheumNow ( View Tweet )
3 days 7 hours ago
Canadian study of 6012 Pregnancies w/ +COVID-19 PCR test shows Preg pts increased risk of hospitalization (RR 2.65) & ICU adm (RR 5.46) vs gen population and higher risk of preterm birth vs preg women without COVID (RR 1.63) https://t.co/6UAaa0Jf8j https://t.co/aLQbxZArmq
Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
FDA update on Paxlovid - for use pts need to have: - COVID test + - Mild-mod dz @ risk for severe COVID - High risk comorbidity - potential interaction w/ statins, OCPs, HIV meds - Dose adjust (nirmatrelvir) w/ CKD - Dose 3 tabs bid x 5d - Watch LFTshttps://t.co/oSqwlKijXq https://t.co/3Yx1C23QSz
Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
RUXCOVID phase 3 RCT ruxolitinib (5mg bid x 14d) + plus standard care in 432 hospitalized COVID-19 showed no benefit over placebo in day 29 primary outcomes (death, respiratory failure (invasive ventilation), or ICU care. https://t.co/eyAit2uOLi https://t.co/R9rA1A4dm5
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 1 day ago
"Belt & Suspenders" strategy - both COVID-19 vaccination & PrEP (Evusheld) needed to prevent SARS-CoV-2 in moderately to severely immunocompromised pts (transplant, cancer, immunodeficiency) and active poorly controlled autoimmune Dz https://t.co/RmflniD7rD https://t.co/K7pmQtqcOb
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
FDA approved 1st drug for kids with COVID-19. Veklury (remdesivir) get an expanded indication in Peds >28days old & wt > 3 kg who has SARS-CoV-2 & are Hospitalized, or Not hospitalized & at high risk for severe COVID-19 or death https://t.co/7Hn4CwKjxv

Dr. John Cush @RheumNow ( View Tweet )

3 weeks 3 days ago
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients Putman et al has reported vaccine survey results from the C19-GRA in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).https://t.co/fIHAhpvVho https://t.co/6tFbQd0vJQ
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 6 days ago
ICYMI: Copenhagen study of COVID & Rheum disease (AIRD) ▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%) ▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6) ▶️ IgG Abs increased if AIRD pt hospitalizedhttps://t.co/VtERRZsGb8 https://t.co/ZwdfNJaAS7
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Despite COVID, revenues for half of top 20 pharma companies grew 10-40% in 2021 Revenues (billions) 1 J&J $97 2 Pfizer $81 3 Roche $62 4 Abbvie $56 5 Novartis $51 6 Merck $48 7 BMS $46 8 GSK $46 9 Sanofi $44 10 AZ $37https://t.co/rSovxIXOId https://t.co/GuKIBYoML6
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
×